Drug Information Related to Pegaptanib Sodium
Back
01. Advances in Treatment of Macular Degeneration
New methods of treatment are emerging to fight macular degeneration which is one of the leading causes of severe vision loss in adults in the US and the developed world.The new drugs include Macugen from Pfizer/Eyetech, Retaane from Alcon, Kenalog and Lucentis. Macuge...
02. OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib...
NEW YORK -- Trial to Study Whether Use of Macugen Following Neovascular AMD Therapy Provides a Balance in Long-Term Safety and Efficacy OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Pfizer Inc. (NYSE: PFE) today announced the initiation of LEVEL (EvaLuation of Effica...
03. Linux: A Comprehensive Hands-On Introduction is Latest Technology ......
RESTON, Va. -- Learning Tree International (NASDAQ NM:LTRE) today announced the addition of a new course to its extensive IT curriculum. The 4-day course, entitled Linux: A Comprehensive Hands-On Introduction, offers participants the opportunity to gain experience wi...
04. OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection...
NEW YORK -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today provided an informational update summarizing highlights from presentations made regarding Macugen(R) (pegaptanib sodium injection) at this year's Association for Research in Vision and Ophthalmology (ARVO) an...
05. Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R...
NEW YORK -- Study results suggest efficacy of selective vascular endothelial growth factor (VEGF) inhibition in treating common cause of vision loss in patients with retinal vascular disease OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today interim Phase II s...
06. O.D. NOTEBOOK | Optometric Management | Find Articles at BNET.com
PEOPLE & PROMOTIONS
...
07. OSI Pharmaceuticals Files Resale Registration Statement for Previously...
MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it filed with the Securities and Exchange Commission a registration statement on Form S-3 for the resale by selling security holders of notes and underlying shares of common stock relating...
08. Nektar Reports That Pfizer and Eyetech Provide Regulatory Update on .....
SAN CARLOS, Calif. -- Nektar Therapeutics (Nasdaq:NKTR) today reported that Pfizer Inc. (NYSE:PFE) and Eyetech Pharmaceuticals, Inc. (Nasdaq:EYET) today said the European Medicines Agency (EMEA) has accepted the filing of their marketing authorization application for ...
09. New drug treats age-related macular degeneration | FDA Consumer | Find...
A new therapy to slow vision loss in people with wet age-related macular degeneration (AMD), an eye disease that destroys central vision, has been approved by the FDA.
...
10. OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen® Maintenance...
NEW YORK -- Trial to Study Whether Use of Macugen Following Neovascular AMD Therapy Provides a Balance in Long-Term Safety and Efficacy
...
11. Resource utilization and costs of age-related macular degeneration ......
INTRODUCTION
...
12. OSI Pharmaceuticals to Announce Second Quarter 2006 Financial Results ...
MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that its second quarter financial results will be released on August 7, 2006 at 5:00pm Eastern Time. At 8:00am on August 8, 2006, OSI will webcast a conference call live on the Company's websit...
13. OSI Pharmaceuticals [OSIP] CEO to Ring The NASDAQ Stock Market Opening...
What:
...
